Nektar Therapeutics | Key People and Executives
Howard W. Robin
President, Chief Executive Officer & Director
Jeffrey Robert Ajer
Independent Director
R. Scott Greer
Independent Director
Dennis L. Winger
Independent Director
Roy A. Whitfield
Independent Director
Christopher A. Kuebler
Independent Director
Lutz Lingnau
Independent Director
Howard W. Robin
President, Chief Executive Officer & Director
John Nicholson
Chief Operating Officer & Senior Vice President
Gilbert M. Labrucherie
Chief Financial Officer & Senior Vice President
Stephen K. Doberstein
Chief Research & Development Officer, Senior R&D
Jonathan Zalevsky
Chief Scientific Officer & Senior VP-Research
Mary Tagliaferri
Chief Medical Officer & SVP-Clinical Development
Lisa Decker
Vice President-Business Development
Maninder Hora
Chief Technical Operations Officer
Brian L. Kotzin
Principal
Jillian B. Thomsen
Chief Accounting Officer & Senior VP-Finance
Jennifer Ruddock
Senior VP-Investor Relations & Corporate Affairs
Jodi A. Sievers
Director-Investor Relations & Communications
Dorian Hirth
Senior VP-Human Resources & Facilities Operations
Mark A. Wilson
Secretary, Vice President & General Counsel
Carlo J. Di Fonzo
Senior VP-Drug Development & Regulatory Affairs
Jeffrey Robert Ajer
Independent Director
R. Scott Greer
Independent Director
Dennis L. Winger
Independent Director
Roy A. Whitfield
Independent Director
Christopher A. Kuebler
Independent Director
Lutz Lingnau
Independent Director
| Address |
455 Mission Bay Boulevard South
San Francisco California 94158
United States
|
|
Employees
|
- |
| Website |
http://www.nektar.com |
| Updated |
07/08/2019 |
| Nektar Therapeutics is a clinical-stage biopharmaceutical company, which engages in developing drug candidates that utilize its PEGylation and polymer conjugate technology platforms. It operates through the United States and Europe geogrpahical segments. The company was founded in 1990 and is headquartered in San Francisco, CA. |
